from Reuters: Health News https://reut.rs/2YFQp4e
Saturday, May 25, 2019
Saturday, May 25, 2019
MZ Digital Marketing Agency
HEALTH NEWS
No comments
The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.

from Reuters: Health News https://reut.rs/2YFQp4e
from Reuters: Health News https://reut.rs/2YFQp4e
Related Posts:
LATEST HEALTH NEWSA federal judge ruled on Monday against birth control organizations that sought to block the Trump administration from shifting a federal family-planning grant program toward prioritizing groups that are faith-based and couns… Read More
LATEST HEALTH NEWSRoche said on Tuesday its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications from flu, a boost to the Swiss drugmaker's efforts to win approval for the single-dose, oral anti-vira… Read More
LATEST HEALTH NEWSA court hearing on a Texas law requiring the burial or cremation of aborted fetal tissue opened on Monday with the state arguing the requirement was a matter of dignity, while abortion providers called it unnecessary and aime… Read More
LATEST HEALTH NEWSSwiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications. fro… Read More
LATEST HEALTH NEWSAbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition. from Reut… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment